Chemotherapy has been reported to induce epithelialmesenchymal transition (EMT) in tumor cells, which is a critical step in the process of metastasis leading to cancer spreading and treatment failure. However, the underlying mechanisms of chemotherapy-induced EMT remain unclear, and the involvement of microRNAs (miRNA) in this process is poorly understood. To address these questions, we established stable chemotherapy-resistant tongue squamous cell carcinoma (TSCC) cell lines CAL27-res and SCC25-res by exposing the parental CAL27 and SCC25 lines to escalating concentrations of cisplatin for 6 months. CAL27-res and SCC25-res cells displayed mesenchymal features with enhanced invasiveness and motility. MiRNA microarray illustrated that miR-200b and miR-15b were the most significantly downregulated microRNAs in CAL27-res cells. Ectopic expression of miR-200b and miR-15b with miRNA mimics effectively reversed the phenotype of EMT in CAL27-res and SCC25-res cells, and sensitized them to chemotherapy, but inhibition of miR-200b and miR-15b in the sensitive lines with anti-sense oligonucleotides induced EMT and conferred chemoresistance. Retrieving the expression of B lymphoma Mo-MLV insertion region 1 homolog (BMI1), a target for miR-200b and miR-15b, in the presence of the miRNA mimics by transfecting CAL27-res cells with pcDNA3.1-BMI1-carrying mutated seed sequences of miR-200b or miR-15b at its 3 0 -UTR recapitulated chemotherapy-induced EMT. In vivo, enforced miR-200b or miR-15b expression suppressed metastasis of TSCC xenografts established by CAL27-res cells. Clinically, reduced miR-200b or miR-15b expression was associated with chemotherapeutic resistance in TSCCs and poor patient survival. Our data suggest that reduced expression of miR-200b and miR-15b underscores the mechanisms of chemotherapy-induced EMT in TSCC, and may serve as therapeutic targets to reverse chemotherapy resistance in tongue cancers.
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Introduction
Tongue squamous cell carcinoma (TSCC) is the most common oral cancer, which frequently leads to malfunction of mastication, speech and deglutition (Toner and O'Regan, 2009) . As one of the standard therapeutic approaches, chemotherapy is effective to reduce tumor size, inhibit distant metastasis and prolong patient survival (Gibson et al., 2005) . However, a large proportion of TSCCs are resistant to chemotherapy, and in these cases chemotherapy may result in more aggressive tumor behaviors and even worse clinical outcome (Seve et al., 2005; Yamauchi et al., 2008) . Previous studies in ovarian carcinoma (Kajiyama et al., 2007) , breast cancer (Hiscox et al., 2006) and colorectal cancer (Yang et al., 2006) have demonstrated that the drug-resistant cancer cells display features of epithelial-mesenchymal transition (EMT), a biological process in which epithelial cells lose cell-cell contact and develop mesenchymal properties, leading to enhanced motility, invasiveness and resistance to apoptosis Thiery et al., 2009) . On the other hand, TWIST1 depletion completely blocks adriamycin-induced EMT and invasiveness (Li et al., 2009b) . Additionally, Notch-2 and its ligand, jagged-1, are upregulated in gemcitabine-resistant pancreatic cancer cells, and inhibition of Notch signaling partially reverses the EMT phenotype . Therefore, chemotherapy-induced EMT in tumor cells has been linked to chemotherapeutic resistance, and determining the mechanisms that govern chemotherapyinduced EMT is essential for development of novel therapeutic strategies to overcome drug resistance.
MicroRNAs (miRNAs) are a class of small non-coding RNAs of B22 nucleotides in size that are endogenously expressed in mammalian cells. They regulate gene expression by repressing mRNA translation or cleaving target mRNA. MiRNAs may function as oncogene or tumor suppressors by modulating multiple cellular pathways, including cell proliferation (Hayashita et al., 2005) , differentiation (Chen et al., 2004; Yu et al., 2007) , apoptosis (Li et al., 2009a; Yu et al., 2010) and invasion (Wellner et al., 2009) . Accumulating evidence has demonstrated that miRNAs have a key role in drug resistance and EMT. For example, miR-221/222 is reported to confer tamoxifen resistance on breast cancer cells by targeting p27Kip1 (Miller et al., 2008) . MiR-15b/ miR-16 modulates multidrug resistance by targeting BCL2 in human gastric cancer cells (Xia et al., 2008) . More interestingly, a recent study has shown a positive feedback loop between NF-kB and miR-448 that has a crucial role in chemotherapy-induced EMT in breast cancer cells (Li et al., 2011) . However, whether miRNAs are involved in regulating chemotherapy-induced EMT in TSCCs remains obscure.
In the present study, we screened for miRNAs that were differentially expressed in the acquired cisplatinresistant TSCC cells, and identified that miR-200b and miR-15b were significantly downregulated. Next we explored the roles of miR-200b, miR-15b and their target B lymphoma Mo-MLV insertion region 1 homolog (BMI1) in regulating chemotherapy-induced EMT in TSCC cells, and evaluated the effects of miR200b and miR-15b expressions on tumor growth and metastasis of chemo-resistant TSCC xenografts. Finally, we correlated the expression of miR-200b, miR-15b and BMI1 with the clinicopathological status and prognosis of TSCC patients.
Results
Cisplatin-resistant cells CAL27-res and SCC25-res have undergone EMT To obtain cisplatin-resistant tongue cancer cells, we treated CAL27 cells and SCC25 cells with escalating concentrations of cisplatin from 10 À7 M to 10 À5 M as reported (Gosepath et al., 2008) . The established CAL27-res cells and SCC25-res cells grow at similar rate in the presence or absence of 10 À5 M cisplatin for 3 days (data not shown). As shown in Figure 1a , the IC 50 of CAL27-res and SCC25-res cells increased by 8 and 7.3 fold, respectively, as compared with their parent lines. Cisplatin also resulted in significantly less apoptosis in CAL27-res and SCC25-res cells than the parent cells (Supplementary Figures S1A & S1B) .
The parent CAL27 and SCC25 cells grew in clusters and were round in shape with tight cell-cell junctions, while CAL27-res cells and SCC25-res cells displayed spindle shape and separated from one other (Figure 1c and Supplementary Figure S1E) . Moreover, quantitative RT-PCR (qRT-PCR) demonstrated that E-cadherin mRNA was reduced by threefold (P ¼ 0.001), while that of vimentin, N-cadherin and fibronectin was increased by 17-(P ¼ 0.011), 7-(P ¼ 0.002) and 21-fold (P ¼ 0.002), respectively, in CAL27-res cells (Supplementary Figure S1C ). Similar observation was achieved in another chemoresistant TSCC line, SCC25-res (Supplementary Figure S1D) . Additionally, western blotting and immunofluorescence staining demonstrated that the protein expression of E-cadherin decreased, while that of vimentin, N-cadherin and fibronectin dramatically increased in chemo-resistant TSCC cells (Figures 1b and c) .
Furthermore, we examined the invasion and migration of chemo-resistant cells using Boyden chamber (Corning, New York, NY, USA) assays. After 22 h of culture, the invasion and migration increased by 16-20 and 9-11-fold in CAL27-res (Figure 1d and Supplementary Figure S1F ) and SCC25-res cells (Figure 1d and Supplementary Figure S1G) , respectively, as compared with their parent lines. This was in consistence with increased motility of CAL27-res cells determined by wound healing assay (Supplementary Figure S1H) . Taken together, our observation indicates that chemoresistant CAL27-res and SCC25-res cells have undergone EMT with enhanced invasiveness and motility.
Reduction of miR-200b and miR-15b induces EMT in TSCC cells
To screen for miRNAs that are involved in the underlying mechanisms of chemotherapy-induced EMT, we employed miRNA microarray. A marked difference in expression was observed in 26 microRNAs between CAL27-res cells and the parent line, including 14 upregulated and 12 downregulated miRNAs. Among them, miR-200b and miR-15b were the most remarkably downregulated microRNAs in CAL27-res cells (Supplementary Table S1 ). qRT-PCR further validated that miR-200b was reduced by 72 and 75% and miR-15b by 69 and 70%, respectively, in CAL27-res and SCC25-res cells versus their parent cells (Figure 2a) . Transfection of the chemo-resistant TSCC cells with miR-200b or miR15b mimics, but not the non-relevant miRNA mimics specifically increased miR-200b or miR-15b level (Figure 2a) .
We next investigated whether ectopic expression of miR-200b or miR-15b may reverse the mesenchymal features and chemo-resistance in TSCC cells. and miR-15b mimics increased E-cadherin, but suppressed vimentin, N-cadherin and fibronectin expression in CAL27-res and SCC25-res cells, respectively, as shown by western blotting (Figure 2b ) and immunofluorescence staining (Figure 2c ). These were further confirmed at mRNA level by qRT-PCR (Supplementary Figures S2A and S3A) . Modified Boyden chamber assay demonstrated that miR-200b and miR-15b mimics synergistically suppressed the invasion and migration of CAL27-res cells (Figure 2d and Supplementary Figure S2B ) and SCC25-res cells (Figure 2d and Supplementary Figure S3B ). Wound healing assay also showed that ectopic expression of miR-200b or miR-15b suppressed the motility of CAL27-res cells (Supplementary Figure S2C ). On the other hand, silencing miR-200b and miR-15b expression in the parent CAL27 and SCC25 cells using anti-sense oligonucleotides (ASO) (Figure 3a ) reduced E-cadherin and increased the expression of vimentin, N-cadherin, fibronectin at both protein (Figures 3b and c) and mRNA levels (Supplementary Figure S4A Figure S7C) . Interestingly, the effect of BMI1-siRNA alone to reverse EMT and chemotherapy resistance of CAL27-res cells is comparable to that of combined treatment with BMI1-siRNA and miR-200b or miR-15b mimics, implying that miR-200b and miR-15b regulate the chemotherapy-induced EMT in TSCC cells via silencing BMI1.
To further corroborate the above hypothesis, we employed a 'rescue' experiment by co-transfecting the CAL27-res cells with mimics of miR-200b or miR-15b and a pcDNA3.1 vector carrying BMI1 expression cassette with mutated seed sequences for miR-200b (BMI1-mut1) or miR-15b (BMI1-mut2) at its 3 0 -UTR. Western blotting demonstrated that co-transfection of CAL27-res cells with MiR-200b and miR-15b in chemotherapy-induced EMT L Sun et al miR-200b mimics and BMI1-mut1 or with miR-15b and BMI1-mut2 retrieved BMI1 protein expression, while cotransfection with a wild-type pcDNA3.1-BMI1 could not recover BMI1 expression silenced by the miRNA mimics (Figure 5a ). Moreover, retrieving BMI1 expression in the cells transfected with the miRNA mimics using BMI1-mut1 or BMI1-mut2 suppressed the expression of E-cadherin and increased that of vimentin, N-cadherin and fibronectin at protein (Figure 5b ) and mRNA levels (Supplementary Figure S8A) . In addition, 'rescuing' BMI1 expression in the presence of miRNA mimics not only enhanced the invasion and migration of CAL27-res Figure S8C) . Collectively, these data suggest that miR-200b and miR-15b regulate chemotherapy-induced EMT of TSCC cells by targeting BMI1.
Enforced miR-200b or miR-15b expression inhibits metastasis of chemo-resistant TSCC xenografts As miR-200b or miR-15b expression inhibits the invasion and migration of chemo-resistant TSCC cells in vitro, we further assessed its effect on tumor growth and metastasis in vivo. miR-200b or miR-15b was stably expressed in CAL27-res cells by transduction with miRNA expressing vector (EmGFP-miR, Supplementary Figure S9 ). As shown in Supplementary Figure  S10A and S10B, enforced expression of miR-200b or miR-15b did not significantly change tumor growth or body weight of the BALB/c-nu mice inoculated with CAL27-res cells subcutaneously.
However, when the mice were xenografted with CAL27 or CAL27-res cells that stably express luciferase, luminrescence imaging for the whole body ( Figure 6a ) and harvested lungs and livers (Figure 6b ) demonstrated that CAL27-res cells metastasized to the lung and liver of tumor-bearing mice, and miR-200b or miR-15b expression suppressed these metastasis. Hematoxylin and eosin staining also showed that miR-200b or miR15b expression inhibited metastasis in the lung and liver of the mice bearing CAL27-res xenografts as compared with non-relevant miRNA (Figure 6c) . Furthermore, the average lung weight of CAL27-res tumor-bearing mice was reduced by miR-200b or miR-15b (Figure 6d ). The number of metastasized tumor cells in the lung and the liver, quantified by qRT-PCR for human hypoxanthine phosphorybosyl transferase in tumor-bearing mice, was reduced by 80 and 70%, respectively, in the animals inoculated with miR-200b or miR-15b expressing CAL27-res cells (Po0.01, Figure 6e ). Hematoxylin and eosin staining of the xenografts also indicated that focal metastasis of CAL27-res tumors was markedly reduced by miR-200b or miR-15b (Supplementary Figure S10C) . Therefore, miR-200b or miR-15b overexpression significantly suppressed the metastasis of CAL27-res xenografts.
Moreover, immunohistochemical staining revealed that miR-200b or miR-15b overexpression reduced BMI1 expression by more than 50% (Po0.01, Supplementary Figure S10C and S10D), but did not influence the percentage of the proliferative PCNA þ tumor cells (P40.05, Supplementary Figure S10C & S10E). These findings suggest that miR-200b and miR-15b inhibit the metastasis of TSCC in vivo probably via silencing BMI1.
Low expression of miR-200b and miR-15b in TSCC is associated with chemotherapeutic resistance and poor patient prognosis
We further evaluated the clinical significance of miR-200b and miR-15b expression in chemotherapeutic resistance and patient prognosis of TSCCs. According to previous studies, TSCCs with progressive disease or stable disease were defined as cisplatin-resistant tumors, while those with partial response or complete response (CR) were defined as cisplatin-sensitive tumors. In-situ hybridization and immunohistochemical staining (Figure 7a ) demonstrated that miR-200b and miR-15b were lower, and BMI1 was higher in chemoresistant TSCCs compared with chemo-sensitive ones. The expression difference between chemo-sensitive and chemo-resistant TSCCs determined by the percentage of positive cells was statistically significant (Figure 7b , Po0.01). In addition, Spearman order correlation analysis showed that BMI1 expression in TSCC was reversely correlated with miR-200b level (Figure 7c , r s ¼ À0.247, P ¼ 0.022) and miR-15b level (r s ¼ À0.497, Po0.001).
Next, we analyzed the association of miR-200b and miR-15b expression with clinicopathological status of TSCC patients (Table 1) . No significant correlation was observed between miR-200b or miR-15b expression and age or sex. However, miR-200b and miR-15b levels were closely associated with lymph node metastasis and chemo-resistance of the patients. Tumors with lymph node metastasis or chemotherapeutic resistance expressed low levels of miR-200b and miR-15b, suggesting that miR-200b and miR-15b downregulation was associated with tumor progression. On the contrary, BMI1 expression was positively correlated with lymph node metastasis and chemo-resistance of TSCCs. Figure S11B , P ¼ 0.002) were associated with better survival. These data suggest that miR-200b and miR-15b expression is inversely correlated with tumor staging and may have a role in the progression of TSCCs.
Discussion
In the current study, we demonstrate that reduction of miR-200b and miR-15b is critical for chemotherapyinduced EMT and drug-resistance of TSCC cells, and ectopic expression of these miRNAs reverses mesenchymal features and represses tumor metastasis of chemoresistant TSCC via silencing BMI1. Furthermore, miR200b and miR-15b levels are negatively associated with lymph node metastasis and chemotherapeutic resistance of TSCC patients, and low miR-200b or miR-15b expression indicates poor prognosis of the patients.
Dysregulation of miRNAs has been well documented in nearly all types of human malignancies, and numerous miRNAs are involved in tumor formation and progression by regulating the expression and action of many oncogenes and tumor suppressor genes. In the present study, we identified Polycomb group protein BMI1 as the functional target, through which miR-200 and miR-15 regulate EMT and chemoresistance.
Previous studies have shown that overexpression of BMI1 alters cell proliferation, apoptosis and stem cell self-renewal and correlates with the invasion and metastasis of several human cancers (Kim et al., 2004 2010). As a Polycomb group protein, BMI1 can repress E-cadherin transcription through PRC1/PRC2-mediated chromatin remodeling and induce EMT directly (Yang et al., 2010) . It also can stabilize Snail, a transcriptional repressor associated with EMT, via modulation of PI3K/Akt/GSK-3b signaling (Song et al., 2009) . Therefore, BMI1 overexpression due to reduction of miR-200b and miR-15b may result in chemotherapyinduced EMT in TSCCs via these pathways. Nevertheless, because one single miRNA might have multiple targets, judicious considerations are essential for identification of the main functional targets. Recent studies have shown that enforced expression of miR-200 family prevents transforming growth factor-b-induced EMT by targeting the E-cadherin transcriptional repressors ZEB1 and SIP1 (Gregory et al., 2008) , and miR-15 controls proliferation and invasion of prostate cancer via silencing CCND1 and WNT3A (Bonci et al., 2008) . However, in the present study, rescue experiment demonstrated that only BMI1 complementary DNA that mutated in miR-200b or miR-15b response element could induce EMT and chemo-resistance in CAL27-res cells that had been inhibited by miR-200b or miR-15b mimics, indicating that miR-200b and miR-15b regulate chemotherapy-induced EMT in TSCC cells mainly via silencing BMI1.
It has been known that the EMT process prevents apoptosis and confers resistance to chemotherapy. For example, Twist1 promotes the association of p53 with Mdm2 and disrupts p53-dependent p21 induction, and depletion of Twist1 can partially reverse multidrug resistance in breast cancer cells (Li et al., 2009b) . Similarly, Snail also confers resistance to paclitaxel, adriamycin and radiation by antagonizing p53-mediated apoptosis (Kajita et al., 2004; Kurrey et al., 2009) . In this study, we identified miR-200b/miR-15b-BMI1 as another important pathway regulating EMT and chemo-resistance of TSCC cells. This is supported by the fact that BMI1 can render apoptotic resistance by enhancing anti-oxidant response (Crea et al., 2010) , activating the IKK-NF-kappaB pathway (Li et al., 2010) or repressing the pro-apoptotic gene Bim (Jagani et al., 2010) . Thus EMT in TSCC cells may contribute to drug resistance either through Twist1 or Snail, which MiR-200b and miR-15b in chemotherapy-induced EMT L Sun et al directly controls EMT process, or through BMI1 that is regulated by EMT-associated miRNAs.
Chemotherapy-resistance is a major issue of treatment in the majority of human tumors, including TSCC. The chemo-resistant cancer cells undergo EMT are known to be the essential initiation for relapse and metastasis. Thus, detecting rationale biomarkers to predict chemotherapy sensitivity and screening for targets to overcome chemotherapy-induced EMT are significant for cancer therapy. As ideal biomarkers should be stable in patient samples to be examined, microRNAs have the advantage for they are relatively more stable as compared with other biological macromolecules. They can be well preserved in tissue samples even after formalin-fixation and paraffin-embedding, and can be efficiently extracted and evaluated (Gilad et al., 2008) . Moreover, microRNAs released from tumor cells are protected in membrane-derived exosomes, and thus are stable in various body fluids including serum and plasma. Changes of microRNA profile in many types of body fluids may reflect potential physiological and/or pathological conditions (Li et al., 2007; Mitchell et al., 2008) , and thus may be applicable in clinics. On the other hand, the development of cancers involves alteration of multiple gene expression, in which a single protein product of oncogene may not accurately reflect the status of the disease. However, a microRNA may regulate multiple coding genes and thus is more likely to predict chemo-sensitivity precisely and effectively. As far as we know, there is no biomarker indicating chemo-resistance or sensitivity of TSCC. Herein, our observation that reduced miR-200b and miR-15b expression in clinical TSCC samples is associated with chemotherapy resistance, and poor patient prognosis may provide surrogates to predict the chemotherapeutic sensitivity for TSCC. However, as a caveat, scarcity of clinical TSCC samples limits the use of primary cultures from patient samples to test our hypothesis that miR-200b and miR-15b reduction mediates chemotherapy-induced EMT.
Finally, our findings demonstrate that overexpression of miR-200b and miR-15b reverses mesenchymal features of chemo-resistant TSCC cells and sensitizes them to drugs. In vivo, enforced miR-200b and miR-15b expression inhibits metastasis and reduces the progression of chemo-resistant TSCC xenografts. Therefore, mimics of miR-200b and miR-15b may provide novel therapeutic strategy against chemoresistant tongue cancers. Many signaling pathways have been targeted to interfere with EMT, including the use of neutralizing antibodies against transforming growth factor-b (Chua et al., 2008) , the inhibition of the Sonic hedgehog-Gli-Snail pathway and RNA interference against transcription factors that induces EMT (Shida et al., 2006; Feldmann et al., 2007) . In contrast to artificially synthetic siRNA, microRNAs are endogenous molecules existing in normal cells, which may minimize their unexpected off-target silencing effects (Krutzfeldt et al., 2005; Jeyaseelan et al., 2007) . Besides, as a microRNA molecule targets to a set of coding genes, rather than a single one, therapies based on microRNA interference could be more potent in cancer treatment by targeting multiple molecular pathways. 
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In summary, our study indicates that miR-200b and miR-15b are effective inhibitors of chemotherapyinduced EMT and tumor metastasis, and consequently have an important role in the development of TSCC. Our results provide a strong rationale for their potential use as therapeutic targets to reverse chemotherapy resistance in tongue cancers.
Materials and methods

Cell culture
Human tongue cancer cell lines CAL27 and SCC25, were purchased from the American Type Culture Collection. The stable cisplatin-resistant lines, CAL27-res and SCC25-res, were established by treating CAL27 or SCC25 with cisplatin (Sigma, St Louis, MO, USA) from 10 À7 M to 10 À5 M, respectively. CAL27 and CAL27-res were cultivated in Dulbecco's modified Eagle's medium (Gibco, Rockville, MD, USA) supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA). SCC25 and SCC25-res were cultivated in Dulbecco's modified Eagle's medium-F12 (Gibco) supplemented with 10% fetal bovine serum and 400 ng/ml hydrocortisone (Sigma).
MTT assay
To monitor resistance to cisplatin, CAL27, CAL27-res cells and SCC25, SCC25-res cells were treated with cisplatin of different concentrations for 24 h. MTT assay was performed as described previously (Li et al., 2009a) . Data were analyzed with software origin 7.5 (OriginLab, Northampton, MA, USA) to fit sigmodial curve. IC 50 is the cisplatin concentration that reduces proliferating cells by 50%.
MiRNA microarray analysis
MicroRNA microarray analyses were performed in CAL27-res cells and CAL27 cells as before (Yu et al., 2007) . A heat map demonstrating the average levels of microRNAs, which are differentially expressed in CAL27-res versus CAL27, was created with DMVS 2.0 software (Chipscreen Biosciences, Shenzhen, China). The differentially expressed microRNAs were listed in Supplementary Table S1 .
Transfection
All miRNA mimics, ASOs for miRNA and BMI1 siRNAs were obtained from GenePharma (Shanghai, China) and their sequences were shown in Supplementary Table S2 . Cells were transfected with 30 nM miRNA mimics, ASOs or siRNA using Lipofectamine 2000 (Invitrogen). EmGFP-miR-200b and EmGFP-miR-15b plasmids were also obtained from GenePharma, and blasticidin (Sigma) was used to select transfected CAL27-res cells. BMI1 complementary DNA carrying a widetype 3 0 -UTR or 3 0 -UTR with mutated seed sequence for miR200b (BMI1-mut1) or mutated seed sequence for miR-15b (BMI1-mut2) (Bhattacharya et al., 2009; Wellner et al., 2009) were cloned into pcDNA 3.1 for 'rescue' experiments.
Quantitative RT-PCR Real-time PCR was carried out using LightCycler 480 (Roche, Basel, Switzerland). Reactions were run in triplicate in three independent experiments. The relative expression of E-cadherin, N-cadherin, vimentin, fibronectin and BMI1 were normalized to b-actin. The primer sequences were shown in Supplementary Table S2 . qRT-PCR for miR-200b and miR-15b were performed using real-time PCR Universal Reagent (GenePharma). U6 was used as an internal control. All the relative expressions in control were set to 1.
Western blotting
Protein extracts were resolved through 8% SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes (BioRad, Berkeley, CA, USA), probed with antibody against human E-cadherin, N-cadherin, vimentin, fibronectin (Santa Cruz, Santa Cruz, CA, USA), BMI1 (Upstate, Bedford, MA, USA) or b-actin (Proteintech, Chicago, IL, USA), and then with peroxidase-conjugated secondary antibody (Proteintech), visualized by chemiluminescence (GE, Fairfield, CT, USA).
Modified boyden chamber assay
In all, 1 Â 10 5 cells were plated into the upper chamber of a polycarbonate transwell filter chamber (Corning, NewYork, NY, USA) and incubated for 22 h. For invasion assay, the upper chamber was coated with Basement Membrane (R&D, Minneapolis, MN, USA). Cells on the lower membrane surface were fixed in 4% paraformaldehyde, stained with crystal violet and counted (5 random 100 Â fields per well). Three independent experiments were performed and the data are presented as the average±s.d.
Immunofluorescence staining
Cells were stained for immunofluorescence on coverslips. After fixation and permeabilization, the cells were incubated with primary antibodies against E-cadherin, N-cadherin, vimentin or fibronectin (Santa Cruz) and then incubated with rhodamine-conjugated or FITC-conjugated secondary antibodies (Invitrogen). The coverslips were counterstained with 46-diamidino-2-phenyl indole and imaged under a confocal microscope TCS SP5 (Lecia, Solms, Germany).
Luciferase reporter assay
We cloned the miR-200b or miR-15b response element (wide type or mutated) in the 3 0 -UTR of BMI1 into pMIR-REPORT plasmid downstream of luciferase reporter gene. Luciferase activities were assayed using a luciferase assay kit (Promega, Madison, WI, USA), and target effect was expressed as relative luciferase activity of the reporter vector with target sequence over the one without target sequence.
Patients and tissue samples
Specimens of locally advanced tongue carcinomas were obtained from Department of Oral & Maxillofacial Surgery of Sun Yat-sen Memorial Hospital, following a protocol approved by the ethics committee. All samples were collected with informed consent. Before surgery, the patients were treated with cisplatin. According to the 'Response Evaluation Criteria in Solid Tumors' of World Health Organization, TSCC with progressive disease or stable disease response were determined as cisplatin-resistant TSCC, while that have partial response or complete response (CR) were determined as cisplatin-sensitive TSCC. The pathological sections for in-situ hybridization and immunohistochemical assay were collected during surgery.
In-situ hybridization This assay was performed according to the manufacturer's protocol (Exiqon, Vedbaek, Denmark). Briefly, after demasking, microRNA was hybridized to 5 0 -DIG-labeled LNA probes. Then the digoxigenins were recognized by a specific anti-DIG antibody that is directly conjugated with alkaline phosphatase. The nuclei were counterstained with haematoxylin.
